Jitters Over Innovative Drug Pricing System Intensify In Korea As FTA Revision Deadline Nears
Executive Summary
Concerns are brewing in South Korea as a deadline to revise the global innovative drug pricing system nears as part of the revised FTA with the US. One lawmaker has asked the government to cautiously negotiate with the US over any revisions to protect the domestic pharma industry and financial status of the national health insurance scheme.